|
WO2017104833A1
|
|
Choroidal neovascularization suppressor or drusen formation suppressor, and method for assessing or screening for same
|
|
WO2015182565A1
|
|
Therapeutic agent for lung disease
|
|
WO2015076425A1
|
|
New monoclonal antibody
|
|
WO2015029948A1
|
|
Prophylactic or therapeutic agent for retinal disease caused by retinal pigment epithelium disorder
|
|
WO2011007853A1
|
|
Monoclonal antibody for cancer-specific isoform
|
|
AU2007225935A1
|
|
Novel pyridine derivative having anti-Helicobacter pylori activity
|
|
WO2007037560A1
|
|
Therapeutic or diagnostic application of sgk2 gene
|
|
WO2007037555A1
|
|
Therapeutic or diagnostic application of dusp15 gene
|
|
WO2007037538A1
|
|
Therapeutic or diagnostic application of spo11 gene
|
|
WO2007037550A1
|
|
Therapeutic or diagnostic application of tsta3 gene
|
|
WO2007037533A1
|
|
Therapeutic or diagnostic application of ppp1r3d gene
|
|
WO2007026960A1
|
|
Use of mocs3 gene for therapeutic or diagnostic purposes
|
|
WO2006118338A1
|
|
Diagnostic agent for tumor
|
|
EP1862804A1
|
|
Method for diagnosis of prostate cancer
|
|
WO2006064861A1
|
|
Function inhibitor of adam10 or adam17 protein and method of screening the same
|
|
AU2003296163A1
|
|
Cell cycle-controlling protein and utilization thereof
|
|
WO2004030688A1
|
|
Novel method of controlling apoptosis by controlling interaction between proteins and drug using the same
|
